Randomized trial assesses oral cancer therapy adherence in Black and White Medicare beneficiaries, indicating targeted improvements are needed.
Key Points
This research aims to evaluate whether the Oncology Care Model improves adherence to oral cancer therapies for specific cancers in Medicare beneficiaries.
Analyzed 2014-2019 Medicare data for beneficiaries prescribed oral cancer drugs.
Used difference-in-differences models to assess adherence changes over time.
Compared OCM-participating practices with propensity-matched practices.
No overall significant impact of OCM on TKIs for CML (DID = -0.3%; 90% CI = -1.2% to 0.6%).
Modest improvements for Black beneficiaries: adherence to TKIs increased by 3.0% (90% CI = 0.2% to 5.8%).
Adherence to antiandrogens similarly improved for Black beneficiaries by 2.2% (90% CI = 0.2% to 4.3%).